Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer
NCT ID: NCT00046787
Last Updated: 2011-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
47 participants
INTERVENTIONAL
2002-09-30
2003-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OSI-211 (Liposomal Lurtotecan)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* One prior treatment of chemotherapy.
* At least three weeks since last chemotherapy treatment and recovery from any related side effects.
* At least three weeks since last chest radiotherapy and at least 10 days since head irradiation and recovery from acute side effects.
* At least one target tumor less than or equal to 20 mm (or less than or equal to 10 mm on spiral CT-scan).
* If a patient has had previous documented Central Nervous System (CNS) involvement, only controlled disease is acceptable.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
OSI Pharmaceuticals
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Clinical Research Center, Inc.
Tucson, Arizona, United States
University of Colorado Health Sciences Center
Denver, Colorado, United States
Baptist Hospital Regional Cancer Ctr.
Knoxville, Tennessee, United States
Vanderbilt Clinical Trials Office
Nashville, Tennessee, United States
Nottingham City Hospital
Nottingham, Nottinghamshire, United Kingdom
Clatterbridge Centre for Oncology
Bebington, Wirral, United Kingdom
Aberdeen Royal Infirmary
Aberdeen, , United Kingdom
Guys Hospital
London, , United Kingdom
Christie Hospital
Manchester, , United Kingdom
Northern Centre for Cancer Research, Newcastle General Hospital
Newcastle upon Tyne, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
110-12
Identifier Type: -
Identifier Source: org_study_id